Business
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
SEATTLE, December 01, 2025--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 – the most upstream and key activator of the alternative pathway of the complement system – and has shown multiple potential advantages over other alternative pathway inhibitors in
About this update from Omeros Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":342,"url":"https://media.zenfs.com/en/business-wire.com/e3d8a4c8164f2e70f5c4dca23195c251"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QIVtX3z6A6IrieZhZtmOkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY4NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e3d8a4c8164f2e70f5c4dca23195c251","width":480,"height":342}},"lazy":false},{"type":"text","content":"SEATTLE, December 01, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 – the most upstream and key activator of the alternative pathway of the complement system – and has shown multiple potential advantages over other alternative pathway inhibitors in development or on the market. The transaction was completed pursuant to an asset purchase and license agreement that was announced on October 15, 2025.","length":669,"tagName":"p"},{"type":"text","content":"Omeros is eligible to receive upfront and near-term milestone payments up to $340.0 million, of which the upfront amount of $240.0 million was paid in cash at closing. In total, Omeros is eligible to receive up to $2.1 billion including potential development and commercial milestones, plus tiered royalties on net sales.","length":321,"tagName":"p"},{"type":"text","content":"Novo Nordisk is strongly positioned to develop zaltenibart into a differentiated and potentially best-in-class treatment approach for a number of rare blood and kidney disorders, maximizing the opportunity to help people living with these diseases in the future and supporting the company’s leadership ambition in this space. Omeros retains rights to its MASP-3 small-molecule program unrelated to zaltenibart, including the ability to develop and commercialize small-molecule MASP-3 inhibitors with limited restrictions on indications.","length":536,"tagName":"p"},{"type":"text","content":"At the closing, Omeros prepaid the entire $67.1 million principal amount outstanding under its senior secured term loan, along with a related pre-payment premium, accrued...